Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mylan to Release 2017 Fourth Quarter and Full Year Results and 2018 Guidance on Feb. 28, 2018
HERTFORDSHIRE, England , and PITTSBURGH , Feb. 8, 2018 /PRNewswire/ --  Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will release its fourth quarter and full year 2017 financial results, as well as its 2018 financial guidance, on Wednesday, Feb. 28 , following the close of the U.S.
View HTML
Toggle Summary Mylan Expands Access to HIV/AIDS Medicines with Launch of First Generic Sustiva® Tablets
- Launch further strengthens Mylan's leading antiretroviral portfolio -- Mylan is eligible for 180 days of exclusivity -
View HTML
Toggle Summary Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
FDA Assigns PDUFA Target Action Date of November 13, 2018
View HTML
Toggle Summary Mylan and Biocon Receive Positive CHMP Opinion for Semglee™, Biosimilar Insulin Glargine
First biosimilar from Mylan and Biocon's joint portfolio recommended for approval in the European Union (EU)
View HTML
Toggle Summary Mylan to Complete $1 Billion Share Repurchase Plan
Abbott sells remaining 20.3 million shares of Mylan
View HTML
Toggle Summary Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)
-- Targeting the initiation of a pivotal patient clinical trial in the first half of 2018 --
View HTML
Toggle Summary Mylan Adds to U.S. Women's Healthcare Portfolio With FDA Approval of First Generic for Estrace® Cream
Mylan now offers estradiol in four delivery methodsThe approval showcases Mylan's ongoing investment in complex products
View HTML
Toggle Summary Biocon and Mylan's Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through their Partner Libbs
BENGALURU, India and HERTFORDSHIRE, England and PITTSBURGH and SAO PAULO , Dec. 29, 2017 /PRNewswire/ -- Biosimilar Trastuzumab, co-developed by Biocon Ltd. (BSE code: 532523, NSE: BIOCON ) and Mylan N.V. (NASDAQ, TASE: MYL), has been approved by ANVISA, the Brazilian regulatory agency, through
View HTML
Toggle Summary Mylan to Present at the 36th Annual J.P. Morgan Healthcare Conference
HERTFORDSHIRE, England and PITTSBURGH , Dec. 20, 2017 /PRNewswire/ --  Mylan N.V. (NASDAQ, TASE: MYL) today announced that its CEO, Heather Bresch , will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. , on Tuesday, Jan. 9, 2018 , at 3 p.m. PT ( 6 p.m. ET ).
View HTML
Toggle Summary Mylan to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
HERTFORDSHIRE, England and PITTSBURGH , Dec. 20, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that its CEO, Heather Bresch , will present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top, in Boston, Mass. , on Thursday, Jan. 4, 2018 , at 4 p.m. ET .
View HTML